Teva Extend Partnership with mAbxience for New Oncology Biosimilar
Friday, October 04, 2024
Teva Pharmaceuticals has entered into a new global licensing agreement with mAbxience.
The agreement focuses on the development of an anti-PD-1 oncology biosimilar candidate and marks the second collaboration between the two companies since their initial partnership in April 2024.
This latest agreement further strengthens the relationship between Teva and mAbxience, aiming to provide affordable, high-quality biosimilars that address unmet needs in oncology care. Both companies will utilise their expertise and resources to drive innovation and improve global access to healthcare solutions.
The deal grants Teva exclusive rights to commercialise the biosimilar in key markets, including Europe and the United States, aligning with mAbxience’s global expansion strategy.
This collaboration supports Teva's ongoing efforts to expand its portfolio of biosimilars under its Pivot to Growth strategy, which focuses on partnerships and business development.
Under the agreement, mAbxience will manage the development and production of the biosimilar in its cGMP-compliant facilities in Spain and Argentina, while Teva will handle regulatory approvals and oversee its commercialisation in the designated markets.
The partnership highlights both companies’ commitment to improving access to vital cancer treatments through the development of biosimilars, enhancing healthcare outcomes worldwide.
Source: tevapharm.com
